Furtek CI - Search Results

1

An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice.

Meinking TL, Clineschmidt CM, Chen C, Kolber MA, Tipping RW, Furtek CI, Villar ME, Guzzo CA. Meinking TL, et al. Among authors: furtek ci. J Pediatr. 2002 Nov;141(5):665-70. doi: 10.1067/mpd.2002.129031. J Pediatr. 2002. PMID: 12410195 Clinical Trial.

2

Effect of within-household reinfestation on design sensitivity.

Chen C, Gould AL, Tipping RW, Guzzo C, Furtek C. Chen C, et al. J Biopharm Stat. 2003 May;13(2):327-36. doi: 10.1081/BIP-120019368. J Biopharm Stat. 2003. PMID: 12729398

3

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC. Guzzo CA, et al. Among authors: furtek ci. J Clin Pharmacol. 2002 Oct;42(10):1122-33. doi: 10.1177/009127002401382731. J Clin Pharmacol. 2002. PMID: 12362927 Clinical Trial.

4

Pharmacokinetics of intravenous and oral losartan in patients with heart failure.

Lo MW, Toh J, Emmert SE, Ritter MA, Furtek CI, Lu H, Colucci WS, Uretsky BF, Rucinska E. Lo MW, et al. Among authors: furtek ci. J Clin Pharmacol. 1998 Jun;38(6):525-32. doi: 10.1002/j.1552-4604.1998.tb05790.x. J Clin Pharmacol. 1998. PMID: 9650542 Clinical Trial.

5

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.

Goldberg MR, Lo MW, Christ DD, Chiou R, Furtek CI, Amit O, Carides A, Biollaz J, Piguet V, Nussberger J, Brunner HR. Goldberg MR, et al. Among authors: furtek ci. Clin Pharmacol Ther. 1997 Jan;61(1):59-69. doi: 10.1016/S0009-9236(97)90182-X. Clin Pharmacol Ther. 1997. PMID: 9024174 Clinical Trial.

6

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Lo MW, et al. Among authors: furtek ci. Clin Pharmacol Ther. 1995 Dec;58(6):641-9. doi: 10.1016/0009-9236(95)90020-9. Clin Pharmacol Ther. 1995. PMID: 8529329 Clinical Trial.

7

Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).

Sandwall P, Lo MW, Jonzon B, Dalén P, Furtek C, Ritter M, Alván G, McCrea J, Sjöqvist F. Sandwall P, et al. Eur J Clin Pharmacol. 1999 Jun;55(4):279-83. doi: 10.1007/s002280050629. Eur J Clin Pharmacol. 1999. PMID: 10424320

8

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM; MK-0974 Protocol 004 study group. Ho TW, et al. Neurology. 2008 Apr 15;70(16):1304-12. doi: 10.1212/01.WNL.0000286940.29755.61. Epub 2007 Oct 3. Neurology. 2008. PMID: 17914062 Clinical Trial.

9

An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection.

Ritter MA, Furtek CI, Lo MW. Ritter MA, et al. Among authors: furtek ci. J Pharm Biomed Anal. 1997 Apr;15(7):1021-9. doi: 10.1016/s0731-7085(96)01948-6. J Pharm Biomed Anal. 1997. PMID: 9160270 No abstract available.

10

Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography.

Furtek CI, Lo MW. Furtek CI, et al. J Chromatogr. 1992 Jan 17;573(2):295-301. doi: 10.1016/0378-4347(92)80132-a. J Chromatogr. 1992. PMID: 1601963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters